January 31, 2015 6:47 AM ET

Biotechnology

Company Overview of Aileron Therapeutics, Inc.

Company Overview

Aileron Therapeutics, Inc., a biopharmaceutical company, develops stapled peptide drugs. The company focuses on candidates targeting cancer, infectious, metabolic, and immune/inflammatory diseases. Its stapled peptides penetrate cells throughout the body; and modulate intracellular and extracellular protein-protein interactions, and critical control points for human diseases. The company has a strategic partnership with Roche. Aileron Therapeutics, Inc. was formerly known as Renegade Therapeutics, Inc. The company was incorporated in 2001 and is based in Cambridge, Massachusetts.

281 Albany Street

Cambridge, MA 02139

United States

Founded in 2001

Phone:

617-995-0900

Fax:

617-995-2410

Key Executives for Aileron Therapeutics, Inc.

Founder
Age: 50
Co-Founder and Vice President of Corporate Development
Chief Financial & Business Officer and Senior Vice President
Chief Operating Officer
Age: 45
Chief Scientific Officer and Senior Vice President of Discovery & Innovative Technologies
Age: 59
Compensation as of Fiscal Year 2014.

Aileron Therapeutics, Inc. Key Developments

Aileron Therapeutics, Inc. Appoints Evan Lippman as Chief Financial and Business Officer

Aileron Therapeutics, Inc. announced that it has expanded its senior management team with the appointment of Evan Lippman as the company's first Chief Financial and Business Officer. Prior to joining Aileron, Mr. Lippman was Senior Vice President at EMD Serono.

Aileron Therapeutics, Inc. Announces New Appointments

Aileron Therapeutics, Inc. announced that it has expanded its senior management team with the appointment of two industry veterans. Manuel C. Aivado, M.D., Ph.D., has joined the company as Chief Medical Officer, and Donna M. Jarlenski will serve as Vice President of Clinical Operations and Program Management. As Chief Medical Officer, Dr. Aivado will be responsible for leading Aileron's global clinical development strategy and implementing the clinical development programs including ALRN-6924. As Vice President of Clinical Operations, Ms. Jarlenski, who joins Aileron from Vertex Pharmaceuticals, will be responsible for the company's clinical operations. She will serve on the senior management team at Aileron and report to Dr. Aivado. Prior to joining Aileron, Dr. Aivado served as Taiho Oncology's Vice President of Clinical Development and Pharmacovigilance. Before joining Aileron, Ms. Jarlenski served as Senior Director, Clinical Development Execution, Global Medicines Development & Affairs at Vertex Pharmaceuticals, where she was responsible for general oversight, strategic budget and resource planning, and corporate alignment of five business units.

Aileron Therapeutics, Inc. Presents at Cowen & Co. 34th Annual Health Care Conference, Mar-04-2014 04:00 PM

Aileron Therapeutics, Inc. Presents at Cowen & Co. 34th Annual Health Care Conference, Mar-04-2014 04:00 PM. Venue: Marriott Copley Place Hotel, Boston, Massachusetts, United States.

Similar Private Companies By Industry

Company Name Region
Velcera, Inc. United States
Agouron Pharmaceuticals, Inc. United States
Vivo Biosciences Inc. United States
Armune BioScience, Inc. United States
Astute Medical, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Aileron Therapeutics, Inc., please visit www.aileronrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.